Pharmacokinetics of intravenous methotrexate in mutant Nagase analbuminemic rats

被引:14
|
作者
Choi, Young H.
Bae, Soo K.
Oh, Jung M.
Sun-Ok, Kim
Lee, Myung G.
机构
[1] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea
[2] Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul 151742, South Korea
[3] Samyang Cent R&D Ctr, Taejon, South Korea
关键词
methotrexate; NARs; pharmacokinetics; glomerular filtration; rats;
D O I
10.1002/bdd.565
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It has been reported that the plasma (or serum) levels of albumin and globulins were lower and higher, respectively, than the serum levels in control rats. Hence, it could be expected that these changes could affect the renal clearance (Cl-r) of methotrexate in Nagase analbuminemic rats (NARs) due to changes in plasma protein binding values. Therefore, methotrexate at a dose of 100mg/kg was administered intravenously to control rats and NARs. The plasma protein binding of methotrexate in NARs was significantly greater (29.4% increase) than the controls, probably due to the considerable binding of the drug (34.2%) to 1.8% beta-plus 0.63% gamma-globulins. The Or of methotrexate in NARs was significantly slower (36.1% decrease) than the controls, due to the significantly smaller Ae(0-24) h (25.8% decrease). The smaller Ae(0-24) h could be due to the significantly smaller free (unbound to plasma proteins) fractions of methotrexate in plasma (13.8% decrease) in NARs, since methotrexate was mainly excreted in the urine via glomerular filtration. However, the Cl-nr values were comparable between the control rats and NARs. This could be because methotrexate is not metabolized considerably via hepatic CYP isozymes based on control rats pretreated with SKF 525-A (a nonspecific inhibitor of hepatic CYP isozymes in rats). Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 50 条
  • [1] Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats
    Kim, EJ
    Suh, OK
    Lee, MG
    [J]. LIFE SCIENCES, 2003, 72 (11) : 1231 - 1245
  • [2] Pharmacokinetics and pharmacodynamics of intravenous azosemide in mutant nagase analbuminemic rats
    Kim, EJ
    Lee, AK
    Kim, SH
    Kim, SG
    Lee, MG
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (02) : 194 - 201
  • [3] Pharmacokinetics and pharmacodynamics of intravenous torasemide in mutant nagase analbuminemic rats
    Kim, EJ
    Lee, MG
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2003, 24 (01) : 27 - 35
  • [4] Ipriflavone Pharmacokinetics in Mutant Nagase Analbuminemic Rats
    Chung, Hye J.
    Kang, Hee E.
    Yang, Kyung H.
    Kim, Sung Y.
    Lee, Myung G.
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2009, 30 (06) : 294 - 304
  • [5] Pharmacokinetics of oltipraz in mutant Nagase analbuminemic rats
    Bae, SK
    Kang, HE
    Kang, MK
    Kim, JW
    Kim, T
    Lee, MG
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (05) : 998 - 1005
  • [6] Pharmacokinetics of drugs in mutant Nagase analbuminemic rats and responses to select diuretics
    Lee, Joo Hyun
    Lee, Young-Joo
    Oh, Euichaul
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2014, 66 (01) : 2 - 13
  • [7] Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant nagase analbuminemic rats: Importance of globulin binding for the pharmacodynamic effects
    Kim, EJ
    Lee, MG
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2001, 22 (04) : 147 - 156
  • [8] THYROXINE TRANSPORT AND DISTRIBUTION IN NAGASE ANALBUMINEMIC RATS
    MENDEL, CM
    CAVALIERI, RR
    GAVIN, LA
    PETTERSSON, T
    INOUE, M
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (01): : 143 - 148
  • [9] Hyperparathyroidism is augmented by ovariectomy in Nagase analbuminemic rats
    Inaba, M
    Morii, H
    Katsumata, T
    Goto, H
    Ishimura, E
    Kawagishi, T
    Kamao, M
    Okano, T
    Nishizawa, Y
    [J]. JOURNAL OF NUTRITION, 2000, 130 (06): : 1543 - 1547
  • [10] Pharmacokinetics of 5-fluorouracil in mutant Nagase analbuminemic rats: Faster metabolism of 5-fluorouracil via CYP1A
    Choi, Young H.
    Bae, Soo K.
    Kim, Sun O.
    Lee, Myung G.
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2007, 28 (02) : 87 - 95